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Reply to the Editor:
Statins are increasingly being used in pa-
tients with coronary disease. Recently,
there has been increasing evidence from
studies conducted in both in vitro and mu-
rine models that low-dose statins promote
angiogenesis and high-dose statins inhibit
it.1 The application of these findings to
patients is limited because of the lack of
translation of the experimental models to
the human setting. It is in this context that
we examined the in vivo effects of high-
dose atorvastatin in a clinically relevant
large animal model of chronic myocardial
ischemia and hypercholesterolemia. We
found that atorvastatin treatment did not
improve endogenous myocardial angiogen-
esis2 or response to growth factor therapy,3
despite improvement in endothelial func-
tion.
Czepluch and Waltenberger make the
important point that the dose of statins used
may be too high for clinical relevance and
indeed may be toxic. The first thing to note
is that, for initial toxicity studies, as much
as 80 mg/kg of atorvastatin was given to
beagle dogs without any observable ad-
verse effects,4 versus the dose of 3 mg/kg
used in our study. Second, when embarking
on these studies, our objective was to
choose a dose that would provide meaning-
ful reductions in total cholesterol and low-
density lipoprotein cholesterol in light of
the model of potent diet-induced hypercho-
lesterolemia being used. Finally, a number
of groups have demonstrated that Akt acti-
vation in response to atorvastatin exposure
occurs in a time-dependent manner; this
has been demonstrated in in vitro studies at
both low and high doses. We have shown
that this Akt activation also occurs in vivo
in the myocardium, and although it may
have detrimental effects, Akt activation is
not in and of itself indicative of statin over-
dose.
Czepluch and Waltenberger appropri-
ately point out that similar experiments
conducted in the setting of normocholester-
olemia and a lower, more clinically rele-
vant statin dose would help to validate our
findings. Indeed, we have recently per-
formed experiments examining a lower sta-
tin dose (1.5 mg/[kg · d], equivalent to 80
mg/d in humans), used routinely in the
clinical setting, in normocholesterolemic
swine (abstract presented at the American
Heart Association, Scientific Sessions
2005, manuscript currently under review).
We found that atorvastatin treatment (1.5
mg/[kg · d] for 20 weeks) was associated
with reduced collateral-dependent myocar-
dial perfusion and reduced endothelial cell
density in the ischemic territory of normo-
cholesterolemic swine relative to control
swine. These animals also demonstrated
impaired coronary microvessel relaxation
in response to growth factors (vascular en-
dothelial growth factor and fibroblast growth
factor) as well as increased myocardial ex-
pression of antiangiogenic protein (en-
dostatin). These findings provide substan-
tial support to the idea that high-dose
statins can impair the myocardial angio-
genic response.
In light of the mounting evidence from
in vitro and now in vivo large animal stud-
ies regarding the antiangiogenic effects of
high-dose statins, it is crucially important
to determine the relevance of these studies
to patients with coronary disease. It may be
that the metabolism of atorvastatin or the
signaling pathways leading to collateral
growth are different in pigs than in human
beings. Yet most preclinical research is
currently performed in this species. The
beneficial effects of statins on clinical out-
comes have been well demonstrated in
large clinical trials. One proposed mecha-
nism for their cholesterol-independent ef-
fects is plaque stabilization, which may
occur through the inhibition of plaque an-
giogenesis. There is also emerging recog-
nition, in the literature, of a possible benefit
of statins in reducing the incidence and
progression of neoplastic processes, which
may also be secondary to their antiangio-
genic effects. Finally, drug-eluting stents
clearly reduce the incidence of restenosis.
Yet there is recent evidence that collateral
growth is impaired by these stents.5 Thus,
the likelihood of vascular occlusion may be
less with these stents, but if it does occur,
there may not be as much collateral reserve,
leading to a high incidence of stent throm-
bosis–related death (40%).
The study of new vessel formation in
the myocardium is a challenging task that
is limited by currently available imaging
modalities (eg, angiography, nuclear imag-
ing, positron emission tomography). Thus
any definitive conclusions regarding the
applicability of these findings to the clini-
cal setting would first require rigorously
designed randomized clinical trials with
appropriately selected end points. These
studies would more clearly define the risks
and benefits of statins, which are increas-
ingly being used at high doses and for
indefinite periods. If proved in clinical
studies, the antiangiogenic properties of
statins would have to be incorporated in the
risk-benefit assessment for the initiation and
maintenance of statin therapy in patients with
coronary disease, in whom collateral vessel
formation can be a lifesaving process.
Munir Boodhwani, MD, MMSc
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Off-pump coronary bypass surgery,
graft patency, and the need of an
informed consent
To the Editor:
We read with interest the article by Lim
and colleagues1 concerning graft patency
after off-pump coronary bypass surgery
(OPCAB). They showed that both patency
and number of distal anastomoses are
lower in OPCAB, which confirms and ex-
tends previous evidence published by our
group concerning reduced patency rates.2-4
The OPCAB technique was developed
and reintroduced in the clinical practice for
economic reasons in some southern America
countries more than a decade ago, and
then it became progressively adopted by
European and North America centers to
reduce trauma, thus rendering coronary by-
pass surgery an easier choice compared
with less invasive options (eg, interven-
tional cardiologic procedures).
In recent years, evidence has accumu-
lated concerning both the pros and cons of
the OPCAB approach. It is now well estab-
lished that OPCAB is associated with a
reduced rate of minor outcomes such as the
incidence of postoperative atrial fibrilla-
tion, the need of blood products, and prob-
ably reduced myocardial enzyme release.4
On the other hand, the risk of reduced
patency and reduced revascularization is an
important issue of OPCAB procedures.
Thus, patients should be extensively in-
formed about the pros and cons of the
OPCAB approach before surgery, and they
should clearly express their acceptance to
undergo OPCAB.
Alessandro Parolari, MD, PhD
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